Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma

Kari E. Sufficool, Donna M. Hepper, Gerald P. Linette, Eva A. Hurst, Dongsi Lu, Anne C. Lind, Lynn A. Cornelius

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Background Activating mutations in BRAF have been observed in up to 60% of melanomas, indicating a pivotal role for kinase deregulation in tumor progression. Vemurafenib is a specific inhibitor of BRAF for treatment of melanomas with activating BRAF V600E mutations and has been a major advancement in melanoma treatment. Treatment with vemurafenib, and to a lesser extent, sorafenib, a relatively non-specific inhibitor of BRAF, has been associated with cutaneous squamous cell carcinoma (SCC). Methods Clinical and microscopic characteristics of cutaneous neoplasms were evaluated following vemurafenib administration. Results Twenty-four of 47 (51%) patients receiving vemurafenib at our institution developed 146 total cutaneous neoplasms, with 75% developing multiple lesions. The median number of lesions in affected patients was three. Body distribution included head/neck (29%), chest/back (21%), upper (23%) and lower extremities (27%). Lesions were biopsied and pathologically showed multiple types of epidermal tumors including, but not limited to, verrucous keratoses with/without partial thickness dysplasia, actinic keratoses and well-differentiated and invasive SCCs with/without keratoacanthomatous features. Conclusions We describe the histopathologic findings of skin lesions potentially associated with vemurafenib. Additional investigation is necessary to further elucidate cutaneous neoplasms associated with vemurafenib; however, frequent dermatologic evaluation is warranted in all patients receiving BRAF inhibitors.

Original languageEnglish
Pages (from-to)568-575
Number of pages8
JournalJournal of cutaneous pathology
Volume41
Issue number7
DOIs
StatePublished - Jul 2014

Keywords

  • BRAF inhibitor
  • keratoacanthoma
  • melanoma
  • squamous cell carcinoma
  • vemurafenib

Fingerprint Dive into the research topics of 'Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma'. Together they form a unique fingerprint.

  • Cite this